1. [1] Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001; 19: 491-496. [DOI:10.1016/S0167-7799(01)01814-5]

2. [2] Johnson JA, Weitzel KW. Advancing pharmacogenomics as a component of precision medicine: how, where, and who? Clin Pharmacol Ther 2016; 99: 154-156. [DOI:10.1002/cpt.273] [PMID] [PMCID]

3. [3] Charlab R, Zhang L. Pharmacogenomics: historical perspective and current status. Methods Mol Biol 2013; 1015: 3-22. [DOI:10.1007/978-1-62703-435-7_1] [PMID]

4. [4] Kasztura M, Richard A, Bempong NE, Loncar D, Flahault A. Cost-effectiveness of precision medicine: a scoping review. Int J Public Health 2019; 64: 1261-1271. [DOI:10.1007/s00038-019-01298-x] [PMID] [PMCID]

5. [5] Plöthner M, Ribbentrop D, Hartman J-P, Frank M. Cost-effectiveness of pharmacogenomic and pharmacogenetic test-guided personalized therapies: a systematic review of the approved active substances for personalized Mmedicine in Germany. Adv Ther 2016; 33: 1461-1480. [DOI:10.1007/s12325-016-0376-8] [PMID] [PMCID]

6. [6] Tekola-Ayele F, Rotimi CN. Translational genomics in low- and middle-income countries: opportunities and challenges. Public Health Genom 2015; 18: 242-247. [DOI:10.1159/000433518] [PMID] [PMCID]

7. [7] Ghaddar F, Saba K, K Zgheib N. Teaching pharmacogenetics in low and middle income countries (LMICS): an empirical study of the lessons learned. Curr Pharmacogenomics Per Med 2012; 10: 217-225. [DOI:10.2174/187569212802510012]

8. [8] Pang T. Pharmacogenomics and personalized medicine for the developing world - Too soon or just-in-time? A personal view from the World Health Organization. Curr Pharmacogenomics Per Med 2009; 7: 149-157. [DOI:10.2174/1875692110907030149]

9. [9] Patrinos GP, Pasparakis E, Koiliari E, Pereira AC, Hünemeier T, Pereira LV, et al. Roadmap for establishing large-scale genomic medicine initiatives in low- and middle-income countries. Am J Hum Genet 2020; 107: 589-595. [DOI:10.1016/j.ajhg.2020.08.005] [PMID] [PMCID]

10. [10] Mitropoulos K, Al Jaibeji H, Forero DA, Laissue P, Wonkam A, Lopez-Correa C, et al. Success stories in genomic medicine from resource-limited countries. Hum Genom 2015; 9: 11. [DOI:10.1186/s40246-015-0033-3] [PMID] [PMCID]

11. [11] Chong HY, Allotey PA, Chaiyakunapruk N. Current landscape of personalized medicine adoption and implementation in Southeast Asia. BMC Genom 2018; 11. [DOI:10.1186/s12920-018-0420-4] [PMID] [PMCID]

12. [12] Warnich L, I Drogemoller B, S Pepper M, Dandara C, EB Wright G. Pharmacogenomic research in South Africa: lessons learned and future opportunities in the rainbow nation. Curr Pharmacogenomics Per Med 2011; 9: 191-207. [DOI:10.2174/187569211796957575] [PMID] [PMCID]

13. [13] Chong HY, Allotey PA, Chaiyakunapruk N. Current landscape of personalized medicine adoption and implementation in Southeast Asia. BMC Medical Genom 2018; 11. [DOI:10.1186/s12920-018-0420-4] [PMID] [PMCID]

14. [14] Rafi I, Crinson I, Dawes M, Rafi D, Pirmohamed M, Walter F. The implementation of pharmacogenomics into UK general practice: a qualitative study exploring barriers, challenges and opportunities. J Community Genet 2020; 11: 269-277. [DOI:10.1007/s12687-020-00468-2] [PMID] [PMCID]

15. [15] Bashir NS, Ungar WJ. The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada. Genome 2015; 58: 527-540. [DOI:10.1139/gen-2015-0100] [PMID]

16. [16] Henderson LK, Craig JC, Willis NS, Tovey D, Webster AC. How to write a Cochrane systematic review. Nephrology 2010; 15: 617-624. [DOI:10.1111/j.1440-1797.2010.01380.x] [PMID]

17. [17] Eden C, Ackermann FJ. Cognitive mapping expert views for policy analysis in the public sector. Eur J Oper Res 2004; 152: 615-630. [DOI:10.1016/S0377-2217(03)00061-4]

18. [18] Bergvall-Kåreborn B, Mirijamdotter A, Basden A. Basic principles of SSM modeling: an examination of CATWOE from a soft perspective. Syst Pract Action Res 2004; 17: 55-73. [DOI:10.1023/B:SPAA.0000018903.18767.18]

19. [19] Wilson B. Soft systems methodology: Conceptual model building and its contribution. 2001.

20. [20] Tuckson RV, Au SM, Berry CE, McGrath BB, Chen C, Evans JP, et al. Realizing the promise of pharmacogenomics: opportunities and challenges. Biotechnol Law Rep 2007; 26: 261-291. [DOI:10.1089/blr.2007.9956]

21. [21] Teutsch S, Tukson R. Realizing the potential of pharmacogenomics: opportunities and challenges. Report of secretary's advisory committee on genetics, health and society 2008; Available from: https://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/sacghs_pharmacogenomics_report1.pdf..

22. [22] Lin JJ, Riely GJ, Shaw AT. Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov 2017; 7: 137-155. [DOI:10.1158/2159-8290.CD-16-1123] [PMID] [PMCID]

23. [23] European U. European Commission Working Document2013 [cited 2019 July 28]. Available from: http://ec.europa.eu/health/files/latest_news/2013-10_personalised_medicine_en.pdf.

24. [24] Knowles L, Luth W, Bubela T. Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges. J Law Biosci 2017; 4: 453-506. [DOI:10.1093/jlb/lsx030] [PMID] [PMCID]

25. [25] Weda M. Personalized Medicine Products: Evaluation of Regulatory Framework. 2014.